Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Akoya Biosciences (Nasdaq: AKYA) announced that its PhenoCycler® Fusion and PhenoImager® HT spatial proteomics platforms will be used in the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program. This UK-based initiative, funded by the Office of Life Sciences and Medical Research Council, aims to advance cancer immunotherapy research through deep multi-omic profiling.
The MANIFEST consortium, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, will study why certain cancer patients respond to immunotherapy while others do not. Akoya's platforms will analyze tissue samples from thousands of cancer patients to identify biomarkers predicting treatment success and potential side effects.
The four-year program will initially evaluate 6,000 patients with breast, bladder, kidney, and skin cancer, with plans to expand to other cancer types. This collaboration aims to improve patient care and advance personalized medicine in cancer immunotherapy.
Akoya Biosciences (Nasdaq: AKYA) ha annunciato che le sue piattaforme di proteomica spaziale PhenoCycler® Fusion e PhenoImager® HT saranno utilizzate nel programma MANIFEST (Analisi Multiomica delle Caratteristiche dell'Immunoterapia per Evidenziare Successo e Tossicità). Questa iniziativa con sede nel Regno Unito, finanziata dall'Ufficio per le Scienze della Vita e dal Consiglio di Ricerca Medica, mira ad avanzare la ricerca sull'immunoterapia del cancro attraverso un'analisi multiomica approfondita.
Il consorzio MANIFEST, guidato dal Francis Crick Institute e dalla Royal Marsden NHS Foundation Trust, studierà perché alcuni pazienti oncologici rispondono all'immunoterapia mentre altri no. Le piattaforme di Akoya analizzeranno campioni di tessuto prelevati da migliaia di pazienti oncologici per identificare biomarcatori che prevedano il successo del trattamento e potenziali effetti collaterali.
Il programma quadriennale valuterà inizialmente 6.000 pazienti affetti da cancro al seno, alla vescica, al rene e alla pelle, con piani di espandere lo studio ad altri tipi di cancro. Questa collaborazione mira a migliorare la cura dei pazienti e ad avanzare la medicina personalizzata nell'immunoterapia per il cancro.
Akoya Biosciences (Nasdaq: AKYA) anunció que sus plataformas de proteómica espacial PhenoCycler® Fusion y PhenoImager® HT se utilizarán en el programa MANIFEST (Análisis Multiómico de las Características de la Inmunoterapia que Demuestran Éxito y Toxicidad). Esta iniciativa con sede en el Reino Unido, financiada por la Oficina de Ciencias de la Vida y el Consejo de Investigación Médica, tiene como objetivo avanzar en la investigación sobre la inmunoterapia del cáncer a través de un perfilado multiómico profundo.
El consorcio MANIFEST, dirigido por el Francis Crick Institute y la Royal Marsden NHS Foundation Trust, estudiará por qué ciertos pacientes con cáncer responden a la inmunoterapia mientras que otros no. Las plataformas de Akoya analizarán muestras de tejido de miles de pacientes con cáncer para identificar biomarcadores que predigan el éxito del tratamiento y posibles efectos secundarios.
El programa de cuatro años evaluará inicialmente a 6.000 pacientes con cáncer de mama, vejiga, riñón y piel, con planes de expandirse a otros tipos de cáncer. Esta colaboración tiene como objetivo mejorar la atención al paciente y avanzar en la medicina personalizada en la inmunoterapia del cáncer.
Akoya Biosciences (Nasdaq: AKYA)는 그들의 PhenoCycler® Fusion 및 PhenoImager® HT 공간 단백질체학 플랫폼이 MANIFEST (면역요법 특징의 다중 오믹스 분석으로 성공과 독성을 증명하는 프로그램)에 사용될 것이라고 발표했습니다. 영국에 본사를 둔 이 이니셔티브는 생명 과학 사무소 및 의료 연구 위원회의 자금 지원을 받아 암 면역 요법 연구를 심층 다중 오믹 프로파일링을 통해 발전시키는 것을 목표로 합니다.
MANIFEST 컨소시엄은 Francis Crick Institute 및 Royal Marsden NHS Foundation Trust가 이끌며, 특정 암 환자들이 면역요법에 반응하는 이유와 그렇지 않은 이유를 연구할 것입니다. Akoya의 플랫폼은 수천 명의 암 환자로부터 조직 샘플을 분석하여 치료 성공과 잠재적인 부작용을 예측하는 바이오마커를 식별할 것입니다.
이 4년 프로그램은 처음에 6,000명의 유방암, 방광암, 신장암 및 피부암 환자를 평가할 예정이며, 다른 암 유형으로 확대할 계획입니다. 이 협력은 환자 치료를 개선하고 암 면역 요법에서 개인 맞춤형 의학을 발전시키는 것을 목표로 합니다.
Akoya Biosciences (Nasdaq: AKYA) a annoncé que ses plateformes de proteomique spatiale PhenoCycler® Fusion et PhenoImager® HT seront utilisées dans le programme MANIFEST (Analyse multiomique des caractéristiques de l'immunothérapie démontrant le succès et la toxicité). Cette initiative basée au Royaume-Uni, financée par l'Office of Life Sciences et le Medical Research Council, vise à faire progresser la recherche sur l'immunothérapie contre le cancer grâce à un profilage multiomique approfondi.
Le consortium MANIFEST, dirigé par le Francis Crick Institute et la Royal Marsden NHS Foundation Trust, étudiera pourquoi certains patients atteints de cancer réagissent à l'immunothérapie tandis que d'autres ne le font pas. Les plateformes d'Akoya analyseront des échantillons de tissus provenant de milliers de patients atteints de cancer afin d'identifier des biomarqueurs prédisant le succès du traitement et les effets secondaires potentiels.
Le programme de quatre ans évaluera initialement 6.000 patients atteints de cancer du sein, de la vessie, des reins et de la peau, avec des projets d'extension à d'autres types de cancer. Cette collaboration vise à améliorer les soins aux patients et à faire progresser la médecine personnalisée dans l'immunothérapie contre le cancer.
Akoya Biosciences (Nasdaq: AKYA) hat bekannt gegeben, dass ihre PhenoCycler® Fusion und PhenoImager® HT räumlichen Proteomik-Plattformen im MANIFEST (Multiomische Analyse der Immuntherapie Merkmale, die Erfolg und Toxizität belegen) Programm eingesetzt werden. Diese im Vereinigten Königreich ansässige Initiative, die von der Office of Life Sciences und dem Medical Research Council finanziert wird, zielt darauf ab, die Forschung zur Immuntherapie von Krebs durch tiefgehende multiomische Profilierung voranzutreiben.
Das MANIFEST-Konsortium, geleitet vom Francis Crick Institute und der Royal Marsden NHS Foundation Trust, wird untersuchen, warum bestimmte Krebspatienten auf die Immuntherapie reagieren, während andere es nicht tun. Die Plattformen von Akoya werden Gewebeproben von Tausenden von Krebspatienten analysieren, um Biomarker zu identifizieren, die den Behandlungserfolg und mögliche Nebenwirkungen vorhersagen.
Das vierjährige Programm wird zunächst 6.000 Patienten mit Brust-, Blasen-, Nieren- und Hautkrebs beurteilen, mit Plänen zur Erweiterung auf andere Krebsarten. Diese Zusammenarbeit zielt darauf ab, die Patientenversorgung zu verbessern und die personalisierte Medizin in der Krebsimmuntherapie voranzubringen.
- Akoya's spatial proteomics platforms selected for use in a major UK-based cancer research initiative
- Participation in MANIFEST consortium enhances Akoya's position in cancer immunotherapy research
- Potential for Akoya's technology to identify key biomarkers for personalized cancer treatment
- Collaboration with leading cancer research institutions and NHS trusts
- None.
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust
Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success
MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that the company’s PhenoCycler® Fusion and PhenoImager® HT spatial proteomics platforms will be used to analyze tissue samples as part of the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program. This multimillion-dollar initiative, funded by the UK Office of Life Sciences (OLS) and the Medical Research Council (MRC), aims to advance cancer immunotherapy research through deep multi-omic profiling.
The MANIFEST consortium brings together leading cancer researchers, academic institutions, NHS trusts, and industry partners, to study why certain cancer patients respond to immunotherapy while others do not. Akoya’s spatial biology platforms will play a pivotal role in profiling immune cell interactions within the tumor microenvironment, offering critical insights into biomarkers that may predict treatment outcomes and potential side effects.
"Akoya Biosciences is proud to be a part of the MANIFEST consortium, contributing our spatial proteomics leadership and expertise with the aim of improving patient care through this groundbreaking effort," said Brian McKelligon, CEO of Akoya Biosciences. "Our technology can help to identify key biomarkers, supporting the consortium’s efforts to advance personalized medicine and ensure that more cancer patients can benefit from the potential of immunotherapy.”
Led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, the four-year MANIFEST program will evaluate thousands of cancer patients undergoing immunotherapy treatments across the UK. Initial testing will include 3000 patients who have completed their treatment and 3000 newly treated patients with breast, bladder, kidney, and skin cancer, with plans to expand to other cancer types.
“In the past decade we have made significant strides with immunotherapy, yet many patients still experience treatment failure or adverse side effects,” said Samra Turajlic, project lead at the Francis Crick Institute and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust. “With MANIFEST, we have a unique opportunity to address these challenges through collaboration and innovation, bringing us closer to more precise and effective cancer treatments.”
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Christine Quern
media@akoyabio.com
FAQ
What is the MANIFEST program that Akoya Biosciences (AKYA) is participating in?
How many patients will be evaluated in the MANIFEST program involving Akoya Biosciences (AKYA)?
Which Akoya Biosciences (AKYA) platforms will be used in the MANIFEST program?
Who are the leading institutions in the MANIFEST consortium that Akoya Biosciences (AKYA) is collaborating with?
